IMCR

28.32

0.33% -0.095

Handel nachbörslich: 28.33 0.005 +0.02%

Immunocore Holdings Plc Adr (IMCR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$28.42

Offen:

$28.7

24-Stunden-Volumen:

279.02K

Relative Volume:

1.04

Marktkapitalisierung:

$1.42B

Einnahmen:

$345.60M

Nettoeinkommen (Verlust:

$-79.01M

KGV:

-22.09

EPS:

-1.2822

Netto-Cashflow:

$-18.62M

1W Leistung:

-2.02%

1M Leistung:

-12.63%

6M Leistung:

-19.35%

1J Leistung:

-51.41%

1-Tages-Spanne:

$27.79

$29.29

1-Wochen-Bereich:

$27.69

$29.91

52-Wochen-Spanne:

$27.69

$76.98

Immunocore Holdings Plc Adr Stock (IMCR) Company Profile

Firmenname

Immunocore Holdings Plc Adr

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

01235 5430281

Adresse

90 PARK DRIVE, OXFORDSHIRE

Mitarbeiter

497

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

IMCR's Discussions on Twitter

Vergleichen Sie IMCR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IMCR Immunocore Holdings Plc Adr	28.32	1.42B	345.60M	-79.01M	-18.62M	-1.6045
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-13	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-11-11	Herabstufung	Mizuho	Outperform → Neutral
2024-10-24	Eingeleitet	UBS	Sell
2024-10-07	Herabstufung	Guggenheim	Buy → Neutral
2024-04-29	Eingeleitet	Leerink Partners	Outperform
2023-11-20	Fortgesetzt	JP Morgan	Overweight
2023-11-02	Eingeleitet	Cantor Fitzgerald	Overweight
2023-10-31	Eingeleitet	Robert W. Baird	Outperform
2023-09-13	Hochstufung	JP Morgan	Neutral → Overweight
2023-09-13	Eingeleitet	Needham	Buy
2023-08-16	Eingeleitet	CapitalOne	Overweight
2023-07-17	Eingeleitet	Canaccord Genuity	Hold
2023-03-31	Eingeleitet	Mizuho	Buy
2023-03-30	Eingeleitet	Guggenheim	Buy
2023-03-24	Eingeleitet	Bryan Garnier	Buy
2022-12-16	Hochstufung	Goldman	Neutral → Buy
2022-11-30	Eingeleitet	Barclays	Overweight
2022-09-09	Eingeleitet	Morgan Stanley	Overweight
2022-09-08	Eingeleitet	Ladenburg Thalmann	Buy
2022-08-08	Eingeleitet	Cowen	Outperform
2022-08-02	Eingeleitet	BTIG Research	Buy
2022-02-08	Eingeleitet	H.C. Wainwright	Buy
2021-10-20	Eingeleitet	Oppenheimer	Outperform
2021-03-02	Eingeleitet	Goldman	Neutral
2021-03-02	Eingeleitet	JP Morgan	Overweight
2021-03-02	Eingeleitet	Jefferies	Buy

Alle ansehen

Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten

Dec 13, 2024

Disappointing data leads to Immunocore stock downgrade by Morgan Stanley - Investing.com South Africa

Dec 13, 2024

Immunocore stock hits 52-week low at $29.23 amid market challenges - Investing.com

Dec 13, 2024

Immunocore's SWOT analysis: TCR pioneer's stock faces pivotal year - Investing.com

Dec 13, 2024

Dec 12, 2024

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy - Yahoo Finance

Dec 12, 2024

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - Yahoo Finance

Dec 12, 2024

New Strong Buy Stocks for December 12th - Yahoo Finance

Dec 12, 2024

Dec 04, 2024

RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart

Dec 04, 2024

Nov 29, 2024

Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? - MSN

Nov 29, 2024

Nov 26, 2024

Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN

Nov 26, 2024

What will it take for small caps to finally outperform large caps on earnings, performance? - MSN

Nov 19, 2024

Nov 17, 2024

Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN

Nov 17, 2024

Nov 13, 2024

Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India

Nov 13, 2024

FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart

Nov 13, 2024

SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart

Nov 13, 2024

Nov 12, 2024

Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - Barchart

Nov 12, 2024

Nov 11, 2024

Mizuho downgrades Immunocore stock to Neutral, slashes PT to $38 from $72 - Investing.com

Nov 11, 2024

Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart

Nov 11, 2024

Nov 09, 2024

Immunocore repays Pharmakon loan, ends agreement - Investing.com India

Nov 09, 2024

Nov 08, 2024

PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Barchart

Nov 08, 2024

Nov 06, 2024

Immunocore Holdings earnings beat by $0.50, revenue topped estimates - Investing.com India

Nov 06, 2024

Oct 24, 2024

Immunocore shares maintain buy rating on HIV treatment potential - Investing.com

Oct 24, 2024

Oct 09, 2024

Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ... - Yahoo Finance

Oct 09, 2024

Oct 03, 2024

Immunocore stock hits 52-week low at $29.72 amid market challenges - Investing.com

Oct 03, 2024

Sep 30, 2024

Immunocore's SWOT analysis: biotech stock poised for growth amid clinical trials - Investing.com UK

Sep 30, 2024

Sep 24, 2024

Financial Fitness Check: Examining Immunocore Holdings plc ADR (IMCR)’s Key Ratios - The Dwinnex

Sep 24, 2024

Sep 23, 2024

Immunocore stock hits 52-week low at $32.07 amid market challenges - Investing.com

Sep 23, 2024

Sep 16, 2024

TD Cowen maintains Buy rating on Immunocore shares on ovarian cancer drug data - Investing.com India

Sep 16, 2024

Quarterly Metrics: Quick and Current Ratios for Immunocore Holdings plc ADR (IMCR) - The Dwinnex

Sep 16, 2024